Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospitals Cleveland Medical Center
With
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Primary Endpoint To determine the effect of a topical application of Valchlor on human subjects at the clinically approved dose.
Secondary Endpoint To establish the efficacy of cholecalciferol (vitamin D3) in reducing skin irritation 48 hours after topical application of Valchlor.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be in general good health
Fitzpatrick Skin Type I-VI
Able to list all current medications and medical conditions
Capable of giving informed consent
You may not be if
Women who are pregnant, nursing, or who may become pregnant in the next 3 months
Participants taking illegal drugs
Currently taking ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil
Currently consuming 800IU or more of vitamin D a day
